



**Perelman School of Medicine, University of Pennsylvania
Smilow Center for Translational Research, Smilow Rubenstein Auditorium & Commons
3400 Civic Center Boulevard, Philadelphia, PA 19104**

8:15 - 8:45 a.m.	Registration and Breakfast	Smilow Commons
8:45 - 9:00 a.m.	Welcome Andrew Tsourkas, PhD , Co-Director, Center for Targeted Therapeutics and Translational Nanomedicine, Professor of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania	Rubenstein Auditorium
9:00 - 9:05 a.m.	Introduction Jake Brenner, MD, PhD , Assistant Professor and Attending Physician, Departments of Medicine and Pharmacology, University of Pennsylvania	
<u>Session I</u>	<u>Keynote Lecture</u> <i>Session Chair: Kara L. Spiller, PhD, Professor, School of Biomedical Engineering, Science, and Health Systems, Drexel University</i>	
9:05 - 9:55 a.m.	<i>“Spatiotemporally Programmed Immunotherapy with Anchored Cytokines”</i> K. Dane Wittrup, PhD , Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge	
<u>Session II</u>	<u>Protein Engineering to Control Our Immune System</u> <i>Session Chair: Patrick Glassman, PhD, Assistant Professor of Pharmaceutical Sciences, School of Pharmacy, Temple University</i>	

9:55 - 10:30 a.m.	<p><i>“Immunotherapy for Atrial Fibrillation Using an Antibody-siRNA Conjugate”</i> Noor Momin, PhD, Assistant Professor, Bioengineering Department and Center for Precision Engineering for Health, University of Pennsylvania</p>	
10:30 - 11:05 a.m.	<p><i>“Unraveling the Mystery of IFN-λ4 and its Signaling Complex Utilizing Computation, Protein Engineering, and cryoEM”</i> Juan Mendoza, PhD, Assistant Professor of Molecular Engineering, Pritzker School of Molecular Engineering and Department of Biochemistry and Molecular Biology, University of Chicago</p>	
11:05 - 11:25 a.m.	Coffee Break	Smilow Commons
<u>Session III</u>	<p><u>Protein Engineering to Control Invaders – Microbes and Cancer</u> <i>Session Chair: Henry Daniell, PhD, Vice-Chair and W.D. Miller Professor, Department of Basic & Translational Sciences, Perelman School of Medicine, University of Pennsylvania</i></p>	Rubenstein Auditorium
11:25 - 12:00 p.m.	<p><i>“Rapid Degradation of Undruggable Proteins via the Lipid Nanoparticle-Mediated Intracellular Delivery of Recombinant bioPROTACs”</i> Andrew Tsourkas, PhD, Professor of Bioengineering, School of Engineering and Applied Science, co-Director, Center for Targeted Therapeutics and Translational Nanomedicine, University of Pennsylvania</p>	
12:00 - 12:35 p.m.	<p><i>“Engineering Antibodies to Outsmart Pathogens”</i> Jennifer Maynard, PhD, Professor of Chemical Engineering, McKetta Department of Chemical Engineering, Cockrell School of Engineering, University of Texas at Austin</p>	
12:35 - 1:45 p.m.	Lunch Break	Smilow Commons
1:45 - 2:30 p.m.	Poster Session (<i>Sponsored by Code Bio</i>)	Smilow Commons
<u>Session IV</u>	<p><u>Chemical Engineering Meets Protein Engineering</u> <i>Session Chair: Mark Sellmyer, MD, PhD, Assistant Professor, Department of Radiology and Department of Biochemistry & Biophysics; Co-Director, The Center for Translational Chemical Biology, University of Pennsylvania</i></p>	Rubenstein Auditorium
2:30 - 3:05 p.m.	<p><i>“Targeted Membrane and Extracellular Protein Degradation via Transferrin Receptor”</i> Xin Zhou, PhD, Assistant Professor of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston</p>	
3:05 - 3:40 p.m.	<p><i>“RNAi in the Era of Nucleic Acid-Based Therapeutics”</i> Vasant Jadhav, PhD, Chief Technology Officer, Alnylam Pharmaceuticals, Cambridge</p>	

3:40 - 4:00 p.m.	Coffee Break	Smilow Commons
<u>Session V</u>	<u>Keynote Lecture</u> <i>Session Chair: Hans Huber, PhD, Adjunct Professor of Systems Pharmacology and Translational Therapeutics, Associate Director, CT³N, Perelman School of Medicine, University of Pennsylvania</i>	Rubenstein Auditorium
4:00 - 4:50 p.m.	<i>“Antibody Drug Conjugates for Cancer Therapy”</i> Peter Senter, PhD , former Vice President, Seagen, and Distinguished Research Fellow in Drug Targeting at Pfizer	
4:50 - 5:00 p.m.	Closing Remarks Vladimir Muzykantov, MD, PhD , Founding Co-Director of the PSOM/SEAS Center for Targeted Therapeutics and Translational Nanomedicine (CT ³ N), Professor of Systems Pharmacology and Translational Therapeutics, Professor of Medicine, University of Pennsylvania	
5:00 - 6:00 p.m.	Reception	Smilow Commons